Head-to-head · WeighScore
Factor Health MD vs Omada Health
The verdict
Factor Health MD takes it — 67.5/100 to 55.6/100.
Factor Health MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Factor Health MD is a Florida-based multi-vertical telehealth platform with an unusually broad GLP-1 lineup — compounded semaglutide, tirzepatide, and the rarely offered liraglutide — plus longevity,…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Factor Health MD | Omada Health |
|---|---|---|
| WeighScore | 67.5/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #171 | #436 |
| Semaglutide | $99/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $149/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #171 · C
Strengths
- Three-GLP-1 lineup including liraglutide — rare in DTC and useful for patients sensitive to newer molecules
- Aggressive $99/mo starting tier with all doses included
- Multi-product platform (GLP-1, longevity, vitamin injectables, men's health, bundles)
- HSA/FSA accepted — uncommon for compounded GLP-1
- St. Petersburg, FL location and phone (305-930-8817) for accountability
Where it loses points
- 503A/503B pharmacy partner not named
- Full states-served list not disclosed
- No named medical director
- FDA compounded-medication disclaimer not prominently displayed
- Corporate legal entity not disclosed
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.